Financial & Business

Zimmer’s Second-Quarter Net Income Jumps 16 Percent

Company lowers 2014 earnings forecast.

Zimmer Holdings Inc. reported a 16 percent increase in second-quarter net income, but the surgical product maker lowered the top end of its 2014 earnings forecast.

The Warsaw, Ind.-based company said its profit increased to $176.5 million, or $1.03 per share, from $152.1 million, or 89 cents per share, in the same quarter a year ago. Earnings, adjusted for one-time gains and costs, came to $1.49 per share. That topped the average analyst forecast by a penny, according to Zacks Investment Research.

The company also said revenue rose 1 percent, to $1.18 billion from $1.17 billion, in the same quarter a year ago. That missed the average Wall Street forecast of $1.2 billion, according to Zacks.

Revenues generated in the Americas were $640 million (down 3 percent year over year at constant exchange rates). The same in Europe grossed $335 million (up 5 percent at constant exchange rates, or CER) while in Asia-Pacific the figure was $208 million (up 7 percent).

Zimmer’s biggest segment – Reconstructive — recorded revenues of $890 million, up 2 percent year over year at CER. This was due to a 7 percent increase in Asia Pacific and 5 percent sales growth in Europe. Revenues in Americas remain at $473 million, unchanged year over year.

Revenues derived from knee implants (within Reconstructive) were up 3 percent year over year at CER to $498 million, while hip implants recorded flat sales of $341 million compared with the prior-year quarter. Revenues from Extremities increased 5 percent year over year to $51 million.

Among the other segments at Zimmer, spine recorded a decline of 4 percent at CER to $52 million whereas trauma increased 6 percent to $79 million in the reported quarter. Dental and Surgical and other group, both disappointed with decline of 1 percent and 10 percent to $61 million and $101 million respectively.

Zimmer’s gross margin contracted 50 basis points (bps) to 71.8 percent in the second quarter. Selling, general and administrative expenses edged down 0.4 percent to $455.8 million while research and development expenses were down 12.4 percent to $48.1 million. As a result, adjusted operating margin expanded 76 bps to 29.2 percent.

Zimmer exited the quarter with cash and cash equivalents and short-term investments of $1.69 billion compared with $1.80 billion as of 2013. Long-term debt increased marginally to $1.69 billion compared with $1.67 billion at the end of 2013.

Year-to-date operating cash flow was $442.9 million compared to $370.2 million in the year-ago period. The company also paid $36.9 million dividend and declared dividends of $22.0 per share during the quarter, an increase of 10 percent year over year.

Zimmer now expects adjusted earnings per share for the year to range between $6 and $6.10. That compares to a previous forecast for $6 to $6.20 per share. It also lowered its forecast for revenue growth to between 2 percent and 3 percent from a previous range of 3 percent to 5 percent.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters